KalVista Pharmaceuticals's total assets for Q1 2026 were $215.50M, a decrease of -14.06% from the previous quarter. KALV total liabilities were $136.34M for the fiscal quarter, a -12.25% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.